Receiving neoadjuvant endocrine therapy enabled many postmenopausal patients with ER+, HER2- breast cancer to undergo breast-conserving surgery.

AstraZeneca and Daiichi Sankyo’s Enhertu's breakthrough therapy designation as a post-neoadjuvant treatment option for ...

Liquid biopsy using ctDNA refines risk stratification for patients with residual cancer burden post-neoadjuvant therapy, ...

The extent of residual prostate cancer in the surgical specimen following intensified neoadjuvant therapy for high-risk localized prostate cancer may predict metastatic recurrence. Residual disease ...

Trastuzumab deruxtecan continues to demonstrate superior safety and efficacy compared with trastuzumab emtansine in patients with high-risk, HER2-positive early breast cancer who have residual ...

Enhertu showed improved iDFS over Kadcyla in early-stage HER2-positive breast cancer with residual disease post-neoadjuvant ...

Neoadjuvant therapy (NT) in patients with melanoma is associated with promising survival benefits, favorable complete response (CR), and an acceptable safety profile, according to systematic review ...

Disclaimer: Trastuzumab deruxtecan has not been approved by the FDA for the neoadjuvant or adjuvant setting for early-stage, ...

Hello. It's Mark Kris from Memorial Sloan Kettering. Recently, I presented information about the published trials of neoadjuvant nivolumab chemotherapy vs chemotherapy, showing robust, disease-free ...

In a propensity score-matched analysis, adjuvant therapy was significantly associated with a higher risk for all-cause and cancer-specific mortality and disease recurrence compared with neoadjuvant ...